Wil Helmus schreef op 7 december 2019 06:32:
Ik denk wachten op resultaten Remlarsen en daarna een emissie:
Remlarsen is currently being evaluated in a Phase 2 clinical trial assessing its safety, tolerability, and activity in the potential prevention or reduction of keloid formation in subjects with a history of keloid scars, a form of pathological scarring. miRagen expects to report interim Phase 2 data from this clinical trial by the end of the year.